Abstract: In heart failure (HF), the heart cannot pump blood efficiently and is therefore unable to meet the body's demands of oxygen, and/or there is increased end-diastolic pressure. Current treatments for HF with reduced ejection fraction (HFrEF) include angiotensin-converting enzyme (ACE) inhibitors, angiotension receptor type 1 (AT 1 ) antagonists, b-adrenoceptor antagonists, aldosterone receptor antagonists, diuretics, digoxin and a combination drug with AT 1 receptor antagonist and neprilysin inhibitor. In HF, the risk of readmission for hospital and mortality is markedly higher with a heart rate (HR) above 70 bpm. Here, we review the evidence regarding the use of ivabradine for lowering HR in HF. Ivabradine is a blocker of an I funny current (I(f)) channel and causes rate-dependent inhibition of the pacemaker activity in the sinoatrial node. In clinical trials of HFrEF, treatment with ivabradine seems to improve clinical outcome, for example improved ejection fraction (EF) and less readmission for hospital, but the effect appears most pronounced in patients with HRs above 70 bpm, while the effect on cardiovascular death appears less consistent. The adverse effects of ivabradine include bradycardia, atrial fibrillation and visual disturbances, but ivabradine avoids the negative inotrope effects observed with b-adrenoceptor antagonists. In conclusion, in patients with stable HFrEF with EF<35% and HR above 70 bpm, ivabradine improves the outcome and might be a first choice of therapy, if beta-adrenoceptor antagonists are not tolerated. Further studies must show whether that can be extended to HF patients with preserved EF.
Heart failure (HF) affects people all over the world and is a major health concern. Nearly 5.8 million people in the USA are affected by HF, and one of nine US death certificates mention HF [1] . HF is more prevalent with increasing age and more men than women are affected, and the life-time risk of developing this condition is an estimated one in five.
Current treatment strategies include angiotensin-converting enzyme (ACE) inhibitors, angiotension receptor type 1 (AT 1 ) antagonists, b-adrenoceptor antagonists (BAA), aldosterone receptor antagonists, diuretics and digoxin, and only if the patient is severely affected, ivabradine or a combination of AT1 receptor antagonist and neprilysin inhibitor (ARNI) is added [2] . The principal aim of this MiniReview was to examine the literature regarding use of ivabradine and investigate the hypothesis that ivabradine may be a first choice of therapy when the resting heart rate (HR) is 70 bpm or higher.
Background
Heart failure is a condition in which the heart cannot pump blood efficiently enough to meet the body's demands of oxygen and/or there is increased end-diastolic pressure [3] . HF can have several causes but often represents itself as a complication or consequence of an underlying cardiovascular disease (CVD). The condition progresses with time and untreated, it will ultimately lead to death. HF can be categorized based on the pathophysiological presentation and is traditionally divided into either heart failure with reduced ejection fraction (HFrEF) or heart failure with preserved ejection fraction (HFpEF) [4] . The newest guidelines from European Society of Cardiology divide HF into three groups HFrEF with EF <40%, heart failure with mid-range ejection fraction (HFmrEF) with EF between 40% and 49% and HFpEF with EF ≥50% [5] .
Heart failure with reduced ejection fraction is a condition where the contractility of the left ventricle (LV) is compromised, whereas HFpEF usually develops as a consequence of chronic hypertension and/or diabetes. HFpEF has previously been synonymous with the term diastolic HF, but lately that nomenclature has been questioned due to the complexity of the disease.
Heart failure with preserved ejection fraction is characterized by left ventricular diastolic dysfunction, involving both abnormal relaxation as well as increased stiffness of the LV. The European Society of Cardiology requires normal or mildly abnormal left ventricular (LV) function and evidence of abnormal LV relaxation, filling, diastolic distensibility and diastolic stiffness for diagnosis of HFpEF [6] .
arrhythmias, congenital heart defects and valvular defects. The correlation especially includes the development of HFrEF after a myocardial infarction and the development of HF with preserved EF as a result of diseases such as hypertension and diabetes [7] .
Hypertension, clinically defined as a blood pressure of 140 systolic over 90 diastolic mmHg or higher, is a major health problem affecting 32.6% of the adult population ≥20 years old in the USA [8] , and this makes it the most common cause of all the risk factors for developing HF [9] . Thus, hypertensive patients have a 28% risk of developing HF during their lifetime [10] .
The high blood pressure increases afterload on the heart, forcing the heart to work harder. This can lead to left ventricular remodelling, initially seen as hypertrophy [11] . The mechanical stress of a high blood pressure along with hormonal changes and growth factor disturbances cause the cardiomyocytes to increase in size along with development of fibrosis. Concentric thickening and hypertrophy of the LV leads to HFpEF which later can also develop into a dilated LV. A dilated LV can also develop directly because of hypertension either with or without myocardial infarction as the facilitator and progress into HFrEF [12] .
Ischaemic heart disease, though not as prevalent as hypertension [1] , remains the most important risk factor for the development of HFrEF. Ischaemic heart disease is a group of syndromes that include angina pectoris, myocardial infarction, sudden cardiac death and arrhythmias. The main factor is reduced blood supply caused by atherosclerotic narrowing of the coronary arteries [3] and apoptosis of the cardiomyocytes after ischaemic events. Other risk factors include age, gender (with higher risk among males), obesity, diabetes and valvular heart disease [1] .
The ventricular dysfunction associated with HF initially leads to impairment of cardiac output (CO). Different compensation mechanisms are activated as a result of this. These include activation of the renin-angiotensin-aldosterone system (RAAS) to retain fluid and thereby increase blood volume, as well as an enlarged sympathetic response, resulting in an elevated resting HR [13] . This tachycardia itself worsens the progression of HF as it increases the metabolic demand of the heart, thus creating a self-enhancing downward spiral. Over time, this alters the excitation-contraction coupling and affects cardiac contractility [14, 15] .
Treatment of Chronic Systolic Heart Failure
HFrEF and HFpEF each constitute about 50% of HF cases, but there are only proven and well-established treatment guidelines for HFrEF. New York Heart Association (NYHA) Functional Classification which organizes patients into the classes I-IV is based on the symptoms and exercise performance of the patient [4] and is used to categorize and as a treatment outcome. The recommended guidelines for the pharmacological treatment of HFrEF in patients with NYHA class II-IV according to the European Society of Cardiology are given in fig. 1 [6] . The first choice of treatment is ACE inhibitors, b-adrenoceptor antagonists and diuretics. If the patient is still NYHA class II-IV, then mineralocorticoid receptor (MR) antagonists are added and if still NYHA class II-IV left ventricular ejection fraction (LVEF) ≤35%, ARNI can replace ACE inhibitors, or if HR ≥70 bpm ivabradine can be added.
Increased resting HR is directly associated with a higher cardiovascular and total mortality [16] . This makes reduction of HR a preferred goal of treatment [17] . Studies show that HF patients with a HR <70 bpm. have a significantly lower mortality and rehospitalization risk than patients with a HR >70 bpm. [18] . A lower HR reduces cardiac work and thereby also the oxygen demand of the heart. It also increases the length of the diastolic phase, which gives a longer perfusion time of the myocardium, as the coronary arteries are perfused during the cardiac diastole [19] . This makes HR lowering a target of angina treatment as well as HF treatment, and as the two can be associated, a treatment goal of HF can involve relief of angina symptoms.
Before the introduction and approval of ivabradine in Europe in 2005 and by the Federal Drug Administration in USA in 2015, b-adrenoceptor antagonists and digoxin were available to reduce HR and rhythm and have been considered in detail in recent reviews [20, 21] .
Ivabradine
Ivabradine is an I funny current (I(f)) inhibitor, inhibiting the pacemaker activity of the sinoatrial (SA) node. For a while, the indication for use of ivabradine has been angina pectoris, but lately, as of 2005 in Europe and 2015 in the USA, it has been approved for the treatment of stable HFrEF with EF <35% and a HR ≥70 bpm, where either BAAs are not tolerated, or maximally tolerated doses are reached without having attained the desired goal of HR<70 bpm [22] .
Understanding the I(f) Current
The action potential (AP) in the SA node is a slow-response AP. Compared to fast-response AP, the upstroke is not as steep and there is no phase 1. The I(f) current is a combined Na + and K + inward current and is responsible for the spontaneous generation of AP in the SA node. It is voltage-regulated and is activated by hyperpolarization with a threshold at about À40/À45 mV. When reaching the threshold, the I(f) current is activated and followed by influx of Na + and K + , stopping the repolarization and facilitating the depolarization process. Later in the depolarization, when the threshold for L-type Ca 2+ channels is reached, these take over mediating an influx of Ca 2+ , further depolarizing the cell resulting in the firing of an AP. The I(f) current closes briefly at the very beginning of the AP, and in this 'Off' mode it briefly acts as an outward current (at positive voltages). When the cell hyperpolarizes again, the I(f) is activated and the cycle continues ( fig. 2 ) [23] . The I(f) current is a member of the hyperpolarization-activated, cyclic nucleotide (CHCN) channel family, which are regulated by the autonomic nervous system. The stimulation of b 1 -adrenoceptors in the SA node increases intracellular levels of cyclic adenosine monophosphate (cAMP) that binds directly to the I(f) channel [24] . This shifts the threshold for activation of I(f) currents to more positive membrane voltages, making it easier for the cell to depolarize fast ( fig. 3 ). The stimulation of b 1 -adrenoceptors thereby has a positive chronotropic effect by acting on the I(f) current [23] . The opposite effect is reached by stimulation of the muscarinic M 2 receptors Fig. 1 . Treatment for a patient with symptomatic HFrEF. ACE-I, angiotensin-converting enzyme inhibitor; ARNI, angiotensin receptor neprilysin inhibitor; EF, ejection fraction; BAA, Beta-adrenoceptor antagonist; CRT, cardiac resynchronization therapy; HFrEF, heart failure with reduced ejection fraction; H-ISDN, hydralazine and isosorbide dinitrate; HR, heart rate; LVAD, left ventricular assist device; LVEF, left ventricular ejection fraction; MR, mineralocorticoid receptor; figure modified from [5] .
in the SA node. This facilitates lowering of cAMP, which in turn lowers the threshold for activation, requiring more hyperpolarization before activation of the I(f) current. This stimulation therefore has a negative chronotropic effect ( fig. 3 ) [7] .
An important notion is that while stimulation of b 1 -adrenoceptors and muscarinic M 2 receptors modulates HR, it does not have an effect on the threshold for firing of the AP nor the shape or duration. Instead, it increases or decreases the depolarization rate during diastole [23] .
Ivabradine Pharmacokinetic and Pharmacodynamic Properties
Ivabradine is a water-soluble drug with a fast intestinal absorption and high first-pass metabolism giving it a bioavailability of about 40%. It is metabolized by CYP3A4 in the intestines and the liver and has a half-life of approximately 11 hr [15] . Ivabradine binds to the subfamily of hyperpolarization-activated, cyclic nucleotide 4 (HCN4) channels, which creates the I(f) current. It diffuses across the cellular membrane and binds intracellularly to the HCN4 channel when it is in its open state [25] .
The number of open channels directly correlates with the amount of depolarizations and hence the number of AP created. This is important in understanding the rate-dependent nature of ivabradine, where a higher HR makes the drug more effective. By blocking the channel and thereby stopping the I (f) current, the depolarization of the SA node cells is prolonged, resulting in lowering of the HR ( fig. 2) [15] .
Ivabradine versus BAAs
As the main effect on HF of both BAAs and ivabradine is reduction in HR, it is reasonable to consider their similarities and differences. A wide spectrum of BAAs are available, they can be divided into different groups based on their haemodynamic properties and receptor affinity (table 1) [26] . Although [14] . (B) The lowering of heart rate as seen in ivabradine treatment by prolonging of depolarization phase [13] . Fig. 3 . Ivabradine inhibits the I(f) channel by binding intracellularly to the channel. Activation of b 1 -adrenoceptors in the sinoatrial node increases cyclic adenosine monophosphate (cAMP), which binds to the I(f) channel. Digoxin acts by inhibiting the Na/K ATPase, and the increase of intracellular calcium is followed by release of acetylcholine, which activates M 2 receptors leading to a decrease in cAMP levels. Binding of cAMP shifts the threshold for activation of I(f) currents to more positive membrane voltages, making it easier for the cell to depolarize fast. Ach, acetylcholine, NA, noradrenaline. different receptor affinity and haemodynamic properties, all badrenoceptor antagonists work through the same cellular mechanism, blocking the b-adrenoceptors which lowers the sympathetic activation of the heart, and thereby reducing HR. This is performed in part by lowering cAMP levels intracellularly. Their negative chronotropic effect is therefore attributable to a decline in the activation of the I funny current in cardiomyocytes.
Although BAAs have been proven to reduce mortality in chronic HF patients [27] and are recommended as part of a first-choice treatment of HF, it is important to note that besides a negative chronotropic effect, the lowered cAMP levels also have a negative inotropic effect. Furthermore, a number of patients do not respond to treatment with BAAs, and some even experience a worsening of their HF symptoms when given these drugs [7] .
The incidence of bradycardia is reported in some of the studies [28] [29] [30] , but the HR-dependent nature of ivabradine means that the risk of developing severe bradycardia when treated with this drug is minimized, as the lower HR obtained also prompts less effect. This is in contrast to the bradycardia often seen in BAA treatment. Furthermore, ivabradine is a specific HR-lowering drug unlike BAAs.
While BAAs do lower the chronotropy of the heart, they also have both negative inotropic and lusitropic effects [31] . Furthermore, it seems that the increased length in diastole attained by both drugs only occurs during rest when treated with BAAs, whereas it is present at rest and during exercise in patients treated with ivabradine [32] . Another important aspect is the lowering of blood pressure that is observed with BAAs, whereas ivabradine fails to change blood pressure. In the CARVIVA study, carvedilol was compared to ivabradine and more patients achieved maximal dose of study treatment in the ivabradine group (88%) than in the carvedilol group (47%) or the combination group (76%). The most frequent reason for suboptimal uptitration in the carvedilol group was excessive blood pressure lowering and for the ivabradine and combination groups, pronounced (<50 bpm) HR reduction [33] .
Clinical Trials with Ivabradine
The number of clinical trials performed, investigating the use of ivabradine, is still low. However, during recent years, the interest has grown considerably, and a greater amount of trials are under way. Table 2 shows the trials that have been completed. The results have constituted a basis for updates on clinical guidelines as well as give insight and better understanding of the HR-lowering effect in both HF patients as well as angina pectoris patients.
The BEAUTIFUL, the SHIFT, the SIGNIFY and the ASSOCIATE studies were randomised, double-blind, placebocontrolled, parallel-group trials. In the BEAUTIFUL trial, patients with coronary artery disease and LVEF <40% were included. The primary end-point was a composite of cardiovascular death, admission to hospital for acute myocardial infarction and admission to hospital for new onset or worsening HF. Ivabradine did not affect the primary composite end-point in any of the subgroups analysed. In a subgroup with HR ≥70 bpm, ivabradine had no effect on cardiovascular death or HF requiring hospital admission. However, it did reduce the incidence of end-points related to coronary artery disease, namely admission to hospital for fatal and non-fatal acute myocardial infarction [28] . In the SHIFT trial, patients with symptomatic HF, LVEF ≤35%, in sinus rhythm with HR ≥70 bpm were included. The primary end-point was the composite of cardiovascular death or hospital admission for worsening HF. Ivabradine treatment reduced the primary end-point, death from HF and all-cause hospitalization but did not reduce all-cause mortality and cardiovascular mortality [30] . The SIG-NIFY study included patients with coronary artery disease, sinus rhythm and HR ≥70 bpm. The primary end-point was a composite of death from cardiovascular causes or non-fatal myocardial infarction. The study showed that for patients who had stable coronary artery disease without clinical HF, the addition of ivabradine did not improve outcome [29] . However, a post hoc analysis applying the SIGNIFY composite end-point on patients with angina at randomization in the SHIFT study revealed that ivabradine numerically reduced the end-points to a similar level in the patient subgroup with angina and similar to the non-angina subgroup, and reduced SHIFT HF outcome to the same degree in these two subgroups [17] . The ASSOCIATE study included patients with chronic stable angina pectoris, previous treatment with atenolol or other beta-blocker agent and HR <60 bpm. Primary end-point was improvement between baseline and end of treatment of the treadmill exercise tolerance test. The patients were randomized to treatment with ivabradine or placebo in addition to atenolol. Ivabradine resulted in significant improvements in exercise capacity relative to placebo in patients with stable angina pectoris receiving beta-blocker therapy [34] . The CARVIVA study included patients with HF class II or III and was a randomized, double-blind comparative study. Patients were allocated to three groups: the BAA carvedilol, ivabradine and carvedilol + ivabradine. Primary end-points, exercise tolerance and maximal oxygen consumption were improved by ivabradine alone and ivabradine in combination with carvedilol as compared to carvedilol treatment. Ivabradine treatment also improved quality of life [35] .
The clinical trials support the idea that HR-lowering with ivabradine does have an effect on HFrEF patients. The reason why the BEAUTIFUL study did not reveal the same effect on the primary end-point like the SHIFT trial, for example reduction in Carvedilol cardiovascular death, hospital admission for worsening of HF (SHIFT) as well as hospital admission for acute myocardial infarction (BEAUTIFUL), could be caused by different study populations. The BEAUTIFUL trial included patients with HR of a minimum of 60 bpm and only found an effect of treatment in patients who had a resting HR of at least 70 bpm. The SHIFT trial, however, found a significant improvement on primary endpoints with ivabradine treatment, but their study population was defined as patients with resting HR of at least 70 bpm -hence, the inclusion criteria were set at the same HR level as the one of the BEAUTIFUL trial found to have an effect. The SHIFT trial found that ivabradine reduced death from HF but not all-cause mortality or cardiovascular mortality. Another important observation is the major improvement in health-related quality of life (HQoL) that was attained in the SHIFT study [36] . Of notion, the BEAUTIFUL study did find positive results in the prevention of coronary artery disease-related end-points, especially admissions for fatal and non-fatal acute myocardial infarction. The investigators did, however, include a broader study population that included different CVDs, whereas the SHIFT trials examined only HFrEF patients [37, 38] .
Ivabradine in the Treatment of HF
The current treatment strategy of HFrEF is well-established and chosen upon sound scientific evidence. Despite this, many patients still experience severe complications to their disease. The prognosis for patients with HF is grave. Studies show that patients admitted to the hospital for HF exhibited a 30-day mortality rate of 10-20%, although a recent nationwide cohort study of HF in Denmark revealed that independent of comorbidity, the mortality rates for 1-and 1-5-year mortality declined from, respectively, 45% and 59% in the period of 1983-1987 to, respectively, 33% and 43% in the period of 2008-2012 [10, 39] .
The use of BAAs is recommended as part of first choice of treatment for HFrEF -mostly because of the understanding that lowering resting HR is a cornerstone in both symptomatic relief and preventing progression of the disease. Despite reduction of HR with BAA improves outcome in patients with HFrEF [40] , the use of BAAs has several difficulties. Only an estimated 20-37% of the patients receive the recommended target dose of BAAs, resulting in a mean resting HR of 70-80 bpm. This is in the high end of HR range and has been associated with an increased mortality risk, as the goal was to obtain a resting HR ≤70 bpm [22] . This leaves a rather large group of patients still in need of treatment, and this paves the road for the use of ivabradine. The European Medicines Agency (EMA) approved ivabradine for use in Europe in patients with HFrEF with LVEF below 35% and a sinus rhythm with a resting HR ≥75 bpm as ivabradine conferred a survival benefit based on a retrospective subgroup analysis requested by EMA [41]. The main effect of ivabradine and the rationalization behind approving it for HF treatment remains the HR-lowering properties which probably improves the effectiveness of the heart (improved work to energy consumption) and allow better diastolic filling of the ventricles; of interest is also the LV remodelling and performance improvements gained while in treatment.
Ivabradine could also be useful in the treatment of HF in patients with asthma or chronic obstructive pulmonary diseases (COPD). Lowering of HR in patients with asthma or COPD by BAAs can have undesirable adverse effects, and due to the risk of bronchoconstriction, they are contra-indicated in patients with asthma, whereas data indicate that patients with COPD tolerate selective beta 1 -adrenoceptor antagonists at low doses [42] . Ivabradine was found to lower HR without causing any effect on pulmonary function and thus could be used for treatment of patients with COPD as well as patients with asthma [43] .
Interestingly, ivabradine has been studied in relation to symptomatic treatment of HFpEF. By applying ivabradine early in the development of the condition, it may delay onset of symptoms. This is due to the better diastolic filling times and lowering of HR during exercise (as this is when symptoms usually occur with HFpEF). This is of great interest considering the poor treatment options currently available for HFpEF [43, 44] . Further research is thus required to give a better understanding and confirmation of these results.
Other Uses of Ivabradine
In addition, research suggests that ivabradine may be useful for more than just HF treatment.
Newer studies suggest that ivabradine might be used to treat inappropriate sinus tachycardia, as described in a recent review [45] . After taking ivabradine, patients reported elimination of >70% of symptoms, with 47% of them experiencing complete elimination; a significant increase in exercise performance was also observed. These effects were associated with a significant reduction of HR [46] .
Ivabradine also proved useful in the treatment of inappropriate sinus tachycardia-induced cardiomyopathy in a pregnant patient, who experienced improvement in both her tachycardia and HF condition; all of this without affecting the child -both in the womb and later while breastfeeding [47] .
Another pregnancy-associated heart condition that might benefit from ivabradine is peripartum cardiomyopathy, which has significant mortality and morbidity rates. Because BAA treatment can be associated with extensive hypotension, sometimes BAA treatment is not an option in these cases. Therefore, the effect of ivabradine has been investigated in small studies and induces significant HR reduction [48] .
Additionally, patients presenting with pulmonary arterial hypertension has been the focus of new long-term ivabradine treatment studies. The standard treatment of pulmonary arterial hypertension consists of phosphodiesterase type 5 inhibitors, endothelin receptor antagonists, and in case that there is no effect on disease progression, prostanoid therapy is an option.
In a limited number of patients with a HR >100 bpm or symptomatic for palpitations adding ivabradine to the standard treatment lowered HR, but also improved 6-min. walking distance and NYHA class [49] . Moreover, there were no adverse effects. These findings show that ivabradine is safe to use in patients with pulmonary arterial hypertension and that larger trials are required to clarify whether there indeed is a positive effect on pulmonary arterial hypertension.
Adverse Effects
Adverse effects observed with ivabradine treatment include bradycardia, atrial fibrillation (AF) and visual disturbances. Bradycardia is considered an expected side effect in a HRlowering drug [50] , and in the BEAUTIFUL trial, 13% of people receiving ivabradine in therapeutic doses were diagnosed with bradycardia -not all of these were symptomatic [37] .
Although rare, AF is a serious adverse effect. The mechanism behind this effect is believed to be a genetic polymorphism in the HCN4 receptors producing an enhanced effect of ivabradine in these patients [15] . On 20 November 2014, EMA made recommendations to reduce risk of heart problems in patients in treatment with ivabradine by recommending that treatment should only be started in patients with HR above 70 and combination of ivabradine with the calcium channel blockers, verapamil and diltiazem should be avoided to prevent marked atrioventricular block. The third recommendation was that the starting dose of ivabradine should not be higher than 5 mg twice daily as a higher dose (10 mg twice daily) was used in the SIGNIFY study, where the incidence of AF was 5.3% in the ivabradine-treated group compared with 3.8% in the placebo group.
In the SHIFT trial, phosphene, which consists of bright illuminations at the periphery of the visual field exacerbated by sudden changes in the ambient level of brightness, occurred in 89% of patients taking ivabradine and only 1% of the placebo group and blurred vision was experienced by 17% in the ivabradine group versus 7% in the placebo group [38] .
The BEAUTIFUL study showed that serious adverse effects were reported by 22.5% of patients in the ivabradine-treated group compared to a reported 22.8% in the control group [37] . This is a consistent finding throughout multiple studies, as reports of different adverse effects were comparable to the prevalence in the placebo groups [17] . However, a proportionally small number of patients do experience the aforementioned side effects, and treatment needs to be adjusted accordingly.
Discussion and Conclusion
The I(f) current has been proven as an effective target for HR-lowering drugs, such as ivabradine in several clinical trials. Ivabradine reduces resting HR to an even greater extent than other HR-lowering drugs like BAAs. Understanding the high impact of HR on the prognosis of HF is of great importance. Furthermore, the negative side effects of ivabradine are obviously smaller than those of BAAs. Ivabradine avoids the negative inotrope effects, and in patients with HFrEF, ivabradine improves the outcome and might be a first choice of therapy when HR is above 70 bpm. In addition, the fact that it is possible to treat patients who do not respond to the usual therapy clearly accentuates the importance of this new treatment option. The positive results in recent clinical trials prompted the approval of ivabradine to treat HFrEF by the FDA in 2015.
Although some doubt still exists about the effects of ivabradine on mortality and morbidity outcome in HF patients, it is well recognized that as a bare minimum, ivabradine positively improves quality-of-life measurements and symptoms, as proven in the SHIFT and BEAUTIFUL studies among others. In addition, a reversion of left ventricular remodelling was found. Ivabradine therapy has a lower risk of bradycardia, which is one of the main problems with other HR-lowering drugs. Bradycardia is mentioned as a side effect, although not as prevalent as reported for other drugs. This is, however, a cause of concern and should be investigated in future studies. Furthermore, ivabradine has shown promising results in the treatment of various other conditions related to cardiac impairment and electrical conduction abnormalities.
Outlook
Heart failure is a major health concern throughout the world. The recent approval of ivabradine to HFrEF patients in the United States is very important, but it does not necessarily mean that it will cause significant change in the treatment regimen practiced in the clinic. The approval was granted in Europe already in 2005, but still, ivabradine remains a treatment option that seems not to be taken often into consideration. Ivabradine has shown promising results, not just as a treatment option when BAAs are not tolerated, but maybe even as a first choice of therapy when the resting HR is 70 bpm or higher. Finally, even when ivabradine will have no great effect on mortality, it is still worth to take into consideration that the drug greatly improves the quality of life for many cardiovascular patients.
